The map of
human disease.
Open to all.

Traditional research data networks aggregate patient records into a central repository — creating a single point of vulnerability, a massive regulatory compliance burden, and an architectural dependence on the vendor who controls the repository. Atlas inverts this model. Each participating institution deploys a local Atlas node that transforms clinical data from its native EHR format into the OMOP Common Data Model, applies HIPAA Safe Harbor de-identification with expert determination validation, and exposes a query interface that responds to federated queries from authorized researchers. The query executes locally against the institution's own data, returns only aggregate or de-identified results to the researcher, and the raw patient data never leaves the institution's firewall. This architecture supports participation from any EHR vendor — Epic, Oracle Health, Meditech, or custom systems — because the transformation to OMOP occurs at the local node, not at the source.

Clinical researchers should not need a data analyst to answer a clinical question. Atlas provides a visual query builder that allows researchers to define cohorts, apply inclusion and exclusion criteria, select outcome variables, and execute queries across the federated network — all through a point-and-click interface that requires no SQL, no programming, and no data engineering expertise. A medical student can define a cohort of patients with type 2 diabetes diagnosed before age 40 who were treated with GLP-1 receptor agonists and measure their 5-year cardiovascular event rate — and receive results from 280 million patient records in under 60 seconds. The same query through a traditional data request process would take 6 to 12 months. Atlas democratizes access to the data that drives medical discovery.

Real-world evidence from observational data is increasingly accepted by the FDA as supplemental evidence for drug safety and effectiveness. Atlas provides the infrastructure for rigorous observational studies at scale: propensity score matching across millions of patients, time-to-event analyses with competing risk adjustment, negative control outcome validation to detect systematic bias, and study design templates that follow OHDSI best practices for distributed network studies. Pharmaceutical companies, academic researchers, and regulatory agencies can execute the same study protocol simultaneously across every participating institution — with results aggregated without any institution sharing patient-level data. This is not retrospective chart review. This is population-scale epidemiology executed in real time.

Eighty percent of clinical trials fail to meet enrollment timelines. The primary reason is not lack of eligible patients — it is inability to find them. Atlas transforms trial feasibility and recruitment by allowing sponsors and investigators to query the federated network with a trial's eligibility criteria before the first site is activated. The system returns de-identified cohort counts by institution, geography, and demographic composition — enabling sponsors to select sites based on actual patient availability rather than investigator reputation. Once a trial is active, Clarion Praxis's auto-screening module identifies eligible patients at participating institutions and presents them to the investigator with a one-click referral to the research coordinator. The connection between Atlas (discovery) and Praxis (enrollment) creates a closed loop from feasibility to accrual that no single-vendor research network can replicate.

Clinical prediction models are only as good as the data they are trained on. A model trained on a single institution's data reflects that institution's patient population, practice patterns, and biases. Atlas enables federated model training where the model travels to the data, trains locally at each participating institution, and returns only model parameters — not patient data — to be aggregated into a global model. This federated learning architecture produces models that are more generalizable, more equitable, and more robust than any single-institution model. Atlas also provides access to pre-trained clinical foundation models — large-scale models trained on billions of structured clinical events that can be fine-tuned for specific prediction tasks: 30-day readmission, disease progression, treatment response, and adverse event risk.

The future of precision medicine depends on linking molecular data to clinical outcomes at population scale. Atlas extends the federated data model to include structured genomic variants, pharmacogenomic profiles, tumor biomarkers, and multi-omics data from participating institutions that perform next-generation sequencing. A researcher studying the relationship between a specific BRCA2 variant and treatment response to PARP inhibitors can query Atlas for patients carrying that variant across the entire network and analyze their longitudinal treatment outcomes, adverse events, and survival data — without any institution sharing identifiable genomic data. This is the infrastructure that makes precision medicine research possible at the scale where rare variants become statistically analyzable.

Research data networks live or die on trust. Institutions must trust that their data will not be misused. Patients must trust that their privacy is protected. IRBs must trust that the regulatory framework is sound. Atlas builds trust through architectural guarantees, not just policies. Differential privacy adds calibrated noise to query results to prevent re-identification of small populations. K-anonymity thresholds suppress results from cells with fewer than a configurable minimum number of patients. Every query is logged with the researcher's identity, institutional affiliation, stated research purpose, and IRB approval status. A community-elected governance council — modeled on the OHDSI governance framework — oversees data use policies, reviews access requests, and audits compliance. The governance is not vendor-controlled. It is researcher-controlled.

Research that never reaches publication changes nothing. Atlas includes a research lifecycle management layer that supports the journey from hypothesis to manuscript. Reproducible study packages capture the complete methodology — cohort definition, variable selection, statistical analysis plan, and code — in a format that can be shared with peer reviewers and re-executed by other researchers on their own institutional data. FAIR data principles (Findable, Accessible, Interoperable, Reusable) are built into every output. Study results can be published to a shared research repository where other institutions can validate findings against their own populations, creating a cycle of discovery, validation, and clinical implementation that accelerates the 17-year bench-to-bedside timeline.